top of page
Lanlin Wu, M.D.




2021年做为联合创始人加入科镁信。科镁信由新加坡生物医药孵化器 EVX Ventures 孵化,专注于运用工程化红细胞和脂质纳米颗粒等新型递送系统进行新一代细胞和基因疗法研发。

Dr. Wu Lanlin is a seasoned life science professional with over 15 years of experience in biopharmaceuticals. Dr. Wu has a wealth of expertise in strategy, marketing, product life cycle management, and regulatory affairs. Throughout her career, she has held key leadership positions at some of the world's leading pharmaceutical companies including Johnson & Johnson, Merck, and Baxter.

Most recently, Dr. Wu served as the CEO of Dendreon China where she was responsible for driving the company's growth and success in the region. Under her leadership, Dendreon China made significant advancements in the life sciences sector, leveraging Dr. Wu's deep understanding of the market and her ability to develop and execute effective strategies.

In addition to her executive roles, Dr. Wu is an active member of the China Medicinal Biotech Association, serving as a Director. She is also the Executive Director of the Tong Xie Yi Cell and Gene Therapy Council, where she works to advance the field of regenerative medicine and promote collaboration between industry leaders and experts.

Dr. Wu holds a Bachelor's degree in Clinical Medicine from Jilin Medical University, where she was also the President of the Student Union. She later pursued an additional degree in business administration in the University of International Business and Economics and an EMBA at China Europe International Business School.

吴岚林 医生


Lanlin Wu, M.D.

Chief Executive Officer

bottom of page